A record 633 biotechnology medicines for more than 100 diseases are under development by companies in the US, according to a new report by industry association the Pharmaceutical Research and Manufacturers of America (PhRMA).

Cancer and related conditions come top of the biotech development league, with 254 medicines either in clinical trials or under review by the US Food and Drug Administration (FDA). The next most populated category is infectious diseases, with 162 biotech drugs in development, followed by autoimmune disorders with 59, HIV/AIDS/related conditions with 34 and cardiovascular disease with 25.

Taken by product class, vaccines dominate the development pipeline with 223 products in clinical trials or under FDA review. They are followed closely by monoclonal antibodies with 192 products in development. In third, fourth and fifth place respectively are recombinant hormones/proteins (66), gene therapies (38) and cell therapies (23).

Most of the products listed by PhRMA are in Phase I or Phase II clinical trials. A total of 157 biotech medicines are in Phase III trials (some of them in Phase II/III) or under FDA review.